Taysha Gene Therapies (TSHA) Misses Q4 EPS by 7c

Taysha Gene Therapies (NASDAQ: TSHA) reported Q4 EPS of ($1.32), $0.07 worse than the analyst estimate of ($1.25).

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Dell’s earning report was bullish for Intel CPU demand, analyst says
• Lynx Equity sees Micron and SanDisk breakout as volatility normalizes